Gritstone Oncology Announces Upcoming Presentation on Novel Shared Neoantigens Included within “Off-The-Shelf” SLATE Immunotherapy at SITC 2019 Annual Meeting
07 oct. 2019 08h00 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
Tempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting
02 oct. 2019 16h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecules...
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
01 oct. 2019 18h01 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
13 nov. 2018 06h30 HE
|
Jounce Therapeutics, Inc.
- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to proceed received for...
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
10 nov. 2018 12h20 HE
|
Jounce Therapeutics, Inc.
- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce...
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
06 nov. 2018 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
02 nov. 2018 13h48 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
19 mars 2018 16h05 HE
|
aTyr Pharma, Inc.
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
21 déc. 2017 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
10 nov. 2017 08h00 HE
|
VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...